ReportGem ReportGem EN

普通外文研报

SUGI HOLDINGS (7649) Fine tuning our estimates and price target, reiterating our Overweight rating

发布日期: 2026-06-23研究机构: JPMorgan公司 / 股票: 7649.T报告页数: 12原文语言: 英语证据页码: 3

研报英文原文证据摘录

SUGI HOLDINGS (7649) Fine tuning our estimates and price target, reiterating our Overweight rating

(2) building a community-based integrated care

model. This involves honing the existing core businesses, specifically (1) expertise

and use of digital transformation (productivity gains in the drugstore and dispensing

businesses and capturing higher-value prescriptions), (2) advancing private brands

(rebranding and stronger product development through supply-chain optimization),

(3) new store openings (the three major metropolitan areas, area dominance, and

combining store formats), and (4) improving ROIC (a shift to asset-light operations

and working-capital improvements).

• The company plans to use cash generated mainly from the core businesses

(drugstores and dispensing) to create and expand adjacent businesses, specifically

broadening customer touchpoints (wellness, inbound demand, and healthcare/

nursing care) and expanding the business model (monetizing data and e-commerce/

OMO models). At the same time, as a consolidation strategy in related areas, the

company cites horizontal integration (continuing its M&A strategy for other

drugstores and dispensing pharmacies, leading industry restructuring through the

provision of infrastructure), and vertical integration (in upstream areas, optimizing

supply chain management (SCM) on the strength of its scale and data). Regarding

the company’s horizontal strategy, we are also watching progress with its tie-up with

Trial Holdings, with which it has formed a comprehensive strategic alliance.

• Regarding its capital policy, the company is stepping up efforts to boost profits

(strengthening health and beauty care (H&BC) and counseling, and boosting the

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器